Observational studyBreast cancer (Tokyo, Japan)2023

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.

Yutaka Yamamoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.